Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.
Press releases published on August 12, 2025
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
GlobeNewswire
·
August 12, 2025
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by Data from Phase 3 STRIVE-ON Safety …
Hydreight Posts Record VSDHOne Growth, Ahead of 2025 Targets
GlobeNewswire
·
August 12, 2025
VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company”), a leader in nationwide digital healthcare solutions, is pleased to provide a corporate update …
Nanox Announces Second Quarter of 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 12, 2025
Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- …
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
GlobeNewswire
·
August 12, 2025
The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement …
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
GlobeNewswire
·
August 12, 2025
U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with …
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire
·
August 12, 2025
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support potential sNDA submission for label expansion …
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
GlobeNewswire
·
August 12, 2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma …
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 12, 2025
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients …
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
GlobeNewswire
·
August 12, 2025
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative …
Global Regenerative Medicine Market Set to Triple, Reaching $49.0 Billion by 2028 | MarketsandMarkets™.
GlobeNewswire
·
August 12, 2025
Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a …
Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK
GlobeNewswire
·
August 12, 2025
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® on-body drug delivery system, announced today that the Brazilian Health Regulatory Agency (Agencia …
Quipt Home Medical Partners With Three Major Health Systems to Form Strategic Joint Venture
GlobeNewswire
·
August 12, 2025
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced it has signed a definitive …
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
GlobeNewswire
·
August 12, 2025
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Total Gross Proceeds …
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 12, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 - …
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
GlobeNewswire
·
August 12, 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic …
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
GlobeNewswire
·
August 12, 2025
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief …
Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis
GlobeNewswire
·
August 12, 2025
San Diego, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis SAN DIEGO – August 12, 2025 – Endure Biotherapeutics, Inc …
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
GlobeNewswire
·
August 12, 2025
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to …
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 12, 2025
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations …
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
GlobeNewswire
·
August 12, 2025
CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, …